By Marcus Chen, MS, Clinical Science Writer. Medically reviewed by Dr. Lila Carter, MD, MPH, Board-Certified Obesity Medicine.
Last March, a woman named Rachel in suburban Phoenix called her telehealth provider in a mild panic. She'd been on liraglutide (Saxenda) for six weeks, losing about a pound a week, and had just read a forum post claiming she should be down 15 pounds by now. "I thought I was broken," she told her prescriber. Her provider pulled up her chart: BMI trending steadily down from 34.2, fasting glucose improving, sleep scores up. Rachel was doing fine. She'd simply compared herself to a trial average she'd misread, on a timeline that didn't apply to her starting dose. That single comparison nearly made her quit.
Most of the bad outcomes around saxenda for weight loss trace back to a handful of avoidable errors like Rachel's. Not drug failures. Not rare side effects. Just patterns of misunderstanding that compound over weeks into real problems. This guide catalogs those patterns and explains how to sidestep each one.
This article is part of the FormBlends ultimate guide to compounded tirzepatide and the GLP-1 Long-Term & Maintenance hub.
Key takeaways
- Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist. Liraglutide (Saxenda) is the older GLP-1 option approved specifically for weight management.
- SURPASS-2 showed greater weight and A1c reduction with tirzepatide versus semaglutide 1 mg in type 2 diabetes over 40 weeks. The comparator dose matters: that's semaglutide 1 mg, not the 2.4 mg dose used for obesity in STEP 1.
- Indirect comparisons for obesity indications also tend to favor tirzepatide, though individual variance is significant.
- Compounded tirzepatide is not FDA-approved. The FDA does not pre-review compounded medications.
The Comparison Problem (and Why It Keeps Coming Up)
"Saxenda for weight loss" is fundamentally a comparison question. People typing it into Google are usually trying to figure out where liraglutide sits relative to the newer GLP-1 agents. The honest answer requires looking at both head-to-head trials and indirect evidence, because the head-to-head data set is small and the comparator doses don't always match the real-world obesity doses.
About 2,900 monthly U.S. searches hit this phrase, which tells you the question has been asked often enough, and answered poorly enough, that a clear written answer is overdue.
Here's the thing about trial data for GLP-1 medications: the numbers are averages. And averages are like the average depth of a river. Perfectly accurate. Completely useless if you're trying to figure out whether you'll drown at the crossing point. The published distribution behind any trial mean contains enormous variation. SURMOUNT-1, for instance, reported substantial differences in response within the same dose arm. That's the normal pattern across the entire GLP-1 class.
Mistake 1: Skipping the Boring Stuff
I'm going to call this what it is: the unsexy checklist problem. Reading the label every time. Verifying the dose in milligrams against the prescription. Confirming the concentration of the current fill. Nobody wants to hear this. It takes less than a minute. It prevents most dosing errors.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The root cause of the majority of dosing mix-ups isn't confusion about pharmacology. It's assumption. Patients assume this fill is the same concentration as the last one. They assume they remember the unit count from three months ago. They assume the syringe markings correspond to the same number of milligrams they injected last week. And then something shifts (a new pharmacy, a new vial concentration) and the assumption breaks.
One minute. Every fill. That's the fix.
Mistake 2: Milligrams vs. Units
Dose instructions are written in milligrams. The syringe is calibrated in units. These are not the same measurement, and applying an outdated unit count to a new concentration is a recurring error that shows up in clinical forums with alarming regularity.
The fix is simple: re-derive the unit count at every new fill rather than relying on memory. If the math doesn't make sense, call the pharmacy before injecting. This is not a sign of incompetence. It's what careful patients do.
Mistake 3: The "Wait and See" Trap
Mild nausea that gradually becomes an inability to keep fluids down. Mild abdominal discomfort that becomes severe and radiating. A new symptom that doesn't fit the typical side-effect pattern. These are not signals to ride it out for another few days.
I'll be blunt: the patients who get into trouble with GLP-1 medications are rarely the ones who call their prescriber too often. They're the ones who wait too long. The threshold for "this warrants a call" should be lower than most people's instincts tell them. Persistent vomiting, severe abdominal pain, or anything that feels categorically different from the expected adjustment period warrants contact with your provider, not a Reddit search.
Mistake 4: Playing Prescriber
Doubling up after a missed dose. Escalating ahead of schedule because the scale isn't moving fast enough. Skipping doses to "reset" tolerance. These are all common impulses. Every single one is a known driver of poor outcomes.
The titration schedule for any GLP-1 medication exists for a reason. It's calibrated to let your GI system adapt. Jumping ahead of it doesn't accelerate results; it accelerates side effects. And skipping doses doesn't reset anything (that's not how receptor pharmacology works).
Adjustments belong in coordination with the prescriber. Full stop.
Mistake 5: Treating the Medication as the Whole Plan
Every published GLP-1 weight-loss trial included a lifestyle component. SURMOUNT-1, STEP 1, the SURPASS series: all of them included calorie guidance and physical-activity recommendations alongside the drug. The published results reflect the combined effect of medication plus lifestyle, not medication alone.
GLP-1 therapy changes the underlying appetite and satiety dynamics. That's genuinely powerful. But it doesn't replace protein intake, resistance training, hydration, and sleep. If anything, it makes those inputs easier to execute and more important to get right, because you're finally in a position where the lifestyle changes can stick.
Protein intake, resistance training, sleep quality, and hydration are the four most commonly underweighted inputs. Each is a small lift to implement. Each is a substantial multiplier on the outcome over months.
Related reading in this cluster
- Tirzepatide Before And After: Complete Guide
- Melanotan 2 Before And After: Complete Guide
- Post Nasal Drip And Ear Pressure: Complete Guide
Mistake 6: Measuring Yourself Against a Mean
This was Rachel's mistake, and it's the most psychologically corrosive one on the list. Trial averages describe a representative participant under trial conditions. They compress an enormous amount of variance into a single number. A patient losing weight more slowly than the trial mean isn't "failing." They're inside the normal distribution that the mean summarizes.
Reading the published distribution behind the average is more useful than reading the average alone. Real-world cohorts add even more variance, primarily from adherence and lifestyle differences. The right mental model treats the trial number as a useful anchor, not a guaranteed destination.
Across the GLP-1 class, the strongest predictor of long-horizon outcome is months on therapy at or near the maintenance dose. Everything else matters less than sustained adherence. Everything.
The Highest-Leverage Habits No One Talks About
Keep a weekly log. Patients who track dose, side effects, hydration, and one wellbeing metric (sleep quality, energy level, whatever feels relevant) consistently get more out of their follow-up visits. It takes five minutes a week. It is, honestly, the single highest-leverage habit in long-term GLP-1 care.
Check storage conditions. A vial exposed to extreme heat in transit, or to freezing, should not be assumed to be at full potency. Call the pharmacy.
Set a recurring refill reminder. Refill cadence is the second most-cited reason patients fall out of adherence, right behind side-effect intolerance. A calendar event prevents most avoidable gaps.
Show up prepared. From the clinician's side, the patient questions that produce the best outcomes are specific, time-bounded, and tied to observed symptoms or measurements. "I noticed mild reflux on the evening of injection day for the past two weeks; here's what I tried" is a far more productive opener than "is reflux normal?" A one-paragraph summary of what changed since the last visit is more useful than fifteen minutes of reconstruction in the exam room.
The patient who arrives prepared and the patient who arrives unprepared receive the same clinical knowledge. The difference in outcome over twelve months is the cumulative effect of every visit being more productive.
Related reading from adjacent topics
How to Course-Correct When Something's Off
The default move when something feels wrong is to call rather than guess. Most prescriber offices and telehealth platforms have a messaging channel that produces a response within one to two business days, which is fast enough for almost every non-emergent concern.
Course correction is easier when the mistake is identified early. The earlier the conversation with the prescriber, the smaller the adjustment required. Waiting three weeks to mention persistent nausea turns a simple dose modification into a longer, more uncomfortable process.
Frequently Asked Questions
Is this question something I should discuss with a clinician?
Yes. Any question that affects how a prescription medication is dosed, stored, or administered is worth raising with your prescriber. The information in this article is general education, not a substitute for individualized clinical guidance.
Which option produces more weight loss on average?
In SURPASS-2, tirzepatide produced greater weight reduction than semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. Indirect comparisons for the obesity indications also tend to favor tirzepatide, but trial-by-trial variance is real and individual response varies considerably.
Is one option safer than the other?
Both share the GLP-1 side-effect profile and class warnings. Differences in tolerability across agents exist but are typically modest at the patient level. The prescriber will weigh comorbidities and contraindications to choose the right starting agent.
Can I switch from one to the other?
Yes, switching is a routine clinical decision. The new agent is typically started at its lowest dose and re-titrated rather than jumping to a "dose-equivalent" on day one.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not an FDA-approved drug. The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing. Compounded medications are dispensed under personalized prescriptions through state-licensed pharmacies when a prescriber determines a personalized formulation is clinically appropriate.
How long should I stay on GLP-1 therapy?
This is a clinical decision, but the data consistently shows that sustained time at or near the maintenance dose is the strongest predictor of long-term outcomes. Stopping early, particularly before reaching a stable maintenance phase, is associated with weight regain in most published cohorts.
What if I'm losing weight more slowly than expected?
Slower-than-average loss is still loss. Review your lifestyle inputs (protein, resistance training, sleep, hydration), confirm your dosing is accurate, and discuss the trajectory with your prescriber. The pace of loss matters far less than whether the trend line is moving in the right direction over months.
Continue the series
Important Safety Information
This article is for educational purposes only and is not medical advice. Compounded tirzepatide and compounded semaglutide are not FDA-approved drugs. The FDA does not review compounded medications for safety, effectiveness, or quality before they are sold. Compounded medications should only be used when a licensed prescriber determines a personalized formulation is clinically appropriate. Do not start, stop, or modify any prescription medication without speaking with a licensed healthcare provider. If you experience symptoms of a serious reaction, including severe abdominal pain, signs of pancreatitis, vision changes, persistent vomiting, signs of an allergic reaction, or thoughts of self-harm, seek emergency care immediately.
FormBlends sells only compounded semaglutide and compounded tirzepatide through licensed U.S. pharmacies after a telehealth evaluation by an independent prescriber. Eligibility, pricing, and formulation are determined on a case-by-case basis.
About this article
Written by Marcus Chen, MS (Clinical Science Writer). Medically reviewed by Dr. Lila Carter, MD, MPH (Board-Certified Obesity Medicine). FormBlends content is reviewed by licensed U.S. clinicians prior to publication. The clinical decisions described above are general education only and should not replace individualized advice from your own healthcare provider.